"Cannabis & Bipolar Disorder"

Bipolar disorder (BD) is a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks. The types of BD and all of them involve clear changes in mood, energy, and activity levels. 

These moods range from periods of extremely “up,” elated, and energized behavior (known as manic episodes) to very sad, “down,” or hopeless periods (known as depressive episodes). Less severe manic periods are known as hypomanic episodes.

How Cannabis Can Be an Effective Treatment for Bipolar Disorder...? 

Studies supporting the use of medical cannabis for Bipolar Disorder and that can help you manage your symptoms with the right treatment plan, but let's see what the studies say...

"Can CBD Help You to Quit Smoking"?

CBD oil is becoming well-known for its potential in  the treatment of a wide variety of health conditions and addictions. 

When it comes to cigarettes, many smokers are triggered by stressful situations as they start to quit smoking... 

Nicotine like other addictive drugs, forms a physical dependence by reprogramming the synaptic receptors in the brain. The nicotine molecule causes a surge of dopamine in the reward centers of the brain, leading to a sense of euphoria.

However, over time the molecule changes the dopamine and other neurochemical receptors to only accept nicotine, meaning consuming the drug is the only way to release dopamine.

When a tobacco user tries to quit, the brain can no longer make the same amount of dopamine. This leads to withdrawal symptoms, the list of which is long and includes: anxiety, depression, weight gain, headaches, problems concentrating, drowsiness or trouble sleeping, and feeling tense, restless, or irritable.

'I smuggled cannabis oil to help my son'

Former police officer Lisa Quarrell never imagined she would break the law - but this year she began smuggling a cannabis product into Scotland.

Lisa, from East Kilbride, travelled to the Netherlands to bring back a medical cannabis oil to give to her six-year-old son Cole, who has severe epilepsy.

Cole has had brain surgery and tried many anti-epileptic drugs, but nothing was helping his seizures.Lisa has spent thousands of pounds to bring the drug back illegally.She told BBC Disclosure: "I'd sell my house. I would. I can't let him get sicker. I need to get him better. There's nothing else for it."

But now her smuggling days could be behind her after Cole was prescribed cannabis oil legally by a private London hospital.Lisa, left policing five years ago to look after Cole, who was diagnosed with severe epilepsy as a baby.

A bad day for Cole could mean up to 16 seizures, most of which would happen at night.She said: "He'll convulse, he'll click in his mouth, his eyes will roll back, he'll drop to the floor with no notice.It's the most heart-breaking thing to watch. Two-and-a-half minutes has never felt so long as when you're watching your child take a seizure."
"Cole had never had a dream because he didn't get to sleep long enough or deep enough to ever have a dream."

Roth Capital Partners Sees Rare Opportunity For Cannabis Industry, MSOs

Roth Capital Partners analyst Scott Fortune said the cannabis industry represents a unique and sizable one-time opportunity as it converts from an illicit market to a legal one. 


The cannabis industry faces a rare opportunity as the drug heads toward a potential rescheduling in the United States. A new Roth Capital report suggests that multistate operators (MSOs) are the most promising companies in the space.

The Thesis

The reasoning behind rescheduling cannabis in the U.S. is three-pronged, Fortune said in a Friday note.

“Quickening favorable public sentiment, progressive legislation and accommodating regulations should eventually deschedule cannabis as a Schedule 1 drug and bring an end to decades of cannabis prohibition,” the analyst said. 

Texts adopted: "Use of cannabis for medicinal purposes" 13/02/2019- Strasbourg

The European Parliament,

–  having regard to Article 168 of the Treaty on the Functioning of the European Union,

–  having regard to the question to the Commission on use of cannabis for medicinal purposes (O-000122/2018 – B8‑0001/2019),

–  having regard to Rules 128(5) and 123(2) of its Rules of Procedure,

A.  whereas the cannabis plant is made up of more than 480 compounds, including over 100 cannabinoids composed of both psychoactive and non-psychoactive compounds whereas many of the compounds constituting the cannabis plant are unique to cannabis

B.  whereas D9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best known cannabinoids identified in cannabis, with THC constituting the main psychoactive and addictive constituent of cannabis while CBD has no intoxicating or addictive properties

C.  whereas the numerous other cannabinoids which make up the cannabis plant, such as cannabichromene, cannabinol, cannabidiolic acid, cannabigerol and tetrahydrocannabivarin, can have neuroprotective effects, can help reduce certain symptoms affecting patients – such as chronic pain, inflammation or bacterial infections – and can stimulate bone growth